# The FDA aims to exclude the active ingredients of these drugs from being used in compounding unless they are officially listed as in short supply.

*biotech · news · 2026-04-30 · Devdiscourse*

## Key points

- The FDA has proposed new regulations targeting compounding of weight-loss drugs' active ingredients.
- Semaglutide, tirzepatide, and liraglutide will be excluded from compounding unless in shortage.
- This move specifically affects Novo Nordisk's Wegovy and Ozempic, and Eli Lilly formulations.
- FDA clarified compounding with bulk substances is unlawful without clinical need if drugs are available.

**Companies:** Novo Nordisk, Eli Lilly
**Countries:** United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3892306-fda-proposes-new-rules-for-weight-loss-drug-compounding)

---

Canonical: https://newsio.io/n/dfe88fdd-c854-4626-9206-1cd46e1d61a3/the-fda-aims-to-exclude-the-active-ingredients-of-these-drugs-from-being-used-in
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works